Bioelectronic medicine company electroCore appoints new CEO

electroCore Inc. has a new CEO.

The Basking Ridge-based bioelectronic medicine company said on Monday Daniel S. Goldberger has been appointed the new head of the organization, effective Oct. 1.

Goldberger, who has more than 35 years of experience in the biotechnology and medical technology industries, most recently served as executive chairman of Repro Med Systems Inc. and had served as its chairman and interim CEO before that.

“I am pleased to welcome Dan to the electroCore team, and believe he is the ideal candidate to lead the company at this critical stage in its ongoing evolution,” Carrie S. Cox, chairman of the board of directors, said. “Dan’s vast experience leading turnarounds and reinvigorating growth across a diverse group of commercial stage medical technology companies will serve us well as we work to extend the reach of our gammaCore noninvasive vagus nerve stimulation device in the U.S., and to new markets and indications. Over the course of his distinguished career, Dan has earned a reputation as a highly respected business leader with a track record of building commercially successful organizations, and the Board looks forward to his immediate contributions.”

“I would also like to thank Frank Amato for his leadership in navigating the company through a successful initial public offering and I wish him well in his future endeavors,” Cox said.

Prior to RMS, he was the CEO of Milestone Medical Inc. and a director and CEO of Xtant Medical Holdings Inc. Before that, he was the director and CEO of Sound Surgical Technologies and before that, Xcorporeal Inc. Earlier in his career, he held a variety of roles at Glucon Inc., OSI Systems, Ohmeda, Nellcor and Hewlett Packard.

“Throughout my career, I have been passionate about helping companies deliver novel medical technologies to patients with unmet needs while building shareholder value,” Goldberger said. “I believe in the broad potential applicability of vagus nerve stimulation across a wide range of indications, and I look forward to working with the highly motivated leadership team at electroCore to fully realize the potential of its proprietary gammaCore non-invasive VNS device.”